Ellagic acid compositions for immune system enhancement

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns an ellagic acid composition for immune system enhancement, differing that additionally is contains chitosan beta-1.3/1.6-glucans or oligosaccharides.

EFFECT: offered composition possesses enhanced immunostimulating effect.

3 ex

 

The invention relates to medicine, in particular the production of medicines.

Ellagic acid SNO, polyphenolic antioxidant is an immunostimulating effective anticancer, antimutagenic agent. It is particularly plentiful in raspberry, pomegranate, walnuts.

Extracts of raspberry, containing ellagic acid, are used in combination with other biologically active ingredients in the treatment of cancer.

US Patent Application 20050136141, July 2005

Ellagic acid stabilizes vitamin C.

US Patent 6,235,721 from 22.05.2001,

Ellagic acid is contained in an amount of 0.5-90% in the pomegranate extract powder in gelatin capsules, used as a secondary drug.

US Patent Application 20060280819 from 18.08.2006, taken as a prototype.

The objective of the invention is to provide compositions based on ellagic acid.

The invention consists in obtaining compositions on the basis of ellagic acid to strengthen the immune system.

The difference of the invention is that in order to enhance the immune system's composition on the basis of ellagic acid are introduced beta-1,3/1,6-glucan or oligosaccharides. Beta-1,3/1,6-glucan derived from yeast (Saccharomyces cerevisial), existing data is a powerful natural biologically as the active ingredient, having a systemic effect, which can be characterized as nonspecific immune stimulation in combination with inactivation of free radicals.

Beta-1,3/1,6-glucans stimulate the receptors in macrophages. This activation triggers a series of events, leading to overall enhanced immune response, which increases:

- the production of leukocytes in the bone marrow, including macrophages, neutrophils and monocytes, which affects foreign objects;

- mobilization of the cells, i.e. the ability to recognize antigens and move to the place of origin;

- phagocytic activity and production of cytokines;

- the formation of endogenous antimicrobial compounds.

Beta-1,3/1,6-glucans are used as secondary drug US Patent 6,143,731 from 07.11.2000,

The oligosaccharides obtained by enzymatic hydrolysis of chitosan, antineoplastic activity. US Patent 6,492,350 from 10.12.2002,

The proposed composition of ellagic acid with beta-1,3/1,6 - glucans or oligosaccharides are not known.

The proposed composition was tested in the SMT BUT "Infectious clinical hospital №2" of Nizhny Novgorod. Confirmed the effect of strengthening the immune system during use of the claimed composition in comparison with pure ellagic acid.

The following examples explain the present invention.

Example 1.

Mixed 4.2 kg of pomegranate extract containing 40,1% ellagic acid production company " Changsha Huir Biological-tech Co.,Ltd" (China) with 2.8 kg of the product obtained from brewer's yeast (Saccharomyces cerevisial) with a content of 85% beta-1,3/1,6-glucans production Leiber gmbh (Germany).

The resulting composition capsulized in gelatine capsules No. 0 in the amount of 350 mg of the composition in the capsule.

Example 2.

Mixed with 4 kg of pomegranate extract of example 1 and 3 kg of chitosan oligosaccharide production LLC Oligomers" THE 9289-008-57184729-03. The resulting composition capsulized in the conditions of example 1.

Example 3.

Mixed 3.8 kg 90%ellagic acid production company "Hangzhou Gosun Biotechnologies Co., Ltd" (China) with 3.2 kg of 85%-tion of beta-1,3/1,6-glucans of example 1.

The resulting composition capsulized in the conditions of example 1.

Clinical testing of the obtained compositions was conducted at the Department of secondary immunodeficieny diseases goose BUT "Infectious clinical hospital № 2" of Nizhny Novgorod with 15.01.2007 on 20.03.2007. It was conducted comparative testing of variants of the composition based on ellagic acid produced by the recipe of LLC "invest-Pharm", as well as the individual components of the composition.

1. Hard gelatin capsules filled with 210 mg of pomegranate extract, containing 40% ellagic acid and 140 mg of product containing 85% of the bet is -1,3/1,6-glucans.

2. Hard gelatin capsules filled with 200 mg of pomegranate extract, containing 40% ellagic acid and 150 mg of oligosaccharides.

3. Hard gelatin capsules filled with 190 mg, 90%ellagic acid and 160 mg of product containing 85% beta-1,3/1,6-glucans.

4. Hard gelatin capsules filled with 190 mg, 90%ellagic acid.

5. Hard gelatin capsules filled with 150 mg of oligosaccharides.

6. Hard gelatin capsules filled with 160 mg of product containing 85%. beta-1,3/1,6-glucans.

To participate in the study were selected with ARVI at least 3-4 times per year, recurrent herpes simplex up to 6-8 times per year, seasonal recurrence of boils.

Experimental group consisted of 60 volunteers (32 males and 28 females) aged 18 to 49 years.

The first group of patients (10 people) received two capsules filled with 210 mg of pomegranate extract, containing 40% ellagic acid and 140 mg of product containing 85% beta-1,3/1,6-glucans.

The second group (10 persons) received two capsules filled with 200 mg of pomegranate extract, containing 40% ellagic acid and 150 mg of chitosan oligosaccharide.

The third group (10 persons) received two capsules filled with 190 mg, 90%ellagic acid and 160 mg of product containing 85% beta-1,3/1,6-glucans.

The fourth group (10) persons received two capsules on anannya 190 mg, 90%ellagic acid.

The fifth group (10 persons) received two capsules filled with 150 mg of oligosaccharides.

The sixth group (10 persons) received two capsules filled with 160 mg of product containing 85% beta-1,3/1,6-glucans.

Patients received two capsules daily for 30 days.

The control group comprised 10 patients with similar premorbid background.

As assessment of effectiveness was used to test the activation of immune cells capable of phagocytosis by the method of the study the phagocytic activity of neutrophils in peripheral blood in comparison with the original data (phagocytic index FIZEAU, PHI 120).

In the first group FIZEAU increased from 61,5+/ - 1.6 per cent to 89,2+/1.4 percent (45%).

PHI 120 increased from 58,9+/-1,7% to 85.8+/ - 1.2 per cent (by 45.7%), approaching normal levels.

The second group was augmentation actively faguoqitirute cells FIZEAU with 59,1+/-1,5% to 76+/ - 1.2 per cent (28, 6%). PHI increased from 120 to 57.1+/ - 1.8 to 72,3% (26.6%).

In the third group noted the growing actively faguoqitirute cells FIZEAU from 58.2+/-1,5% up to 91.2+/-1,4% (53.8 per cent). PHI 120 increased from 58.5+/-1,4% to 92.3+/ - 1.2 per cent (57,7%).

In the fourth group marked increase in cells FIZEAU with 59,0+/-1,5% to 67.2+/ - 1.2 per cent (13.5%). PHI 120 increased from 57.0+/ - 1.8 to 66,5+/-1,7% (16.7%).

In the fifth group of the marked increase in cells FIZEAU with 59,0+/-1,5% to 62.7+/-1,4% (6.3%). FI increased from 57,1+/-1,7% up to 62.1+/ - 1.6 per cent (8.7%).

In the sixth group noted the network increase actively faguoqitirute cells FIZEAU with 59,1+/-1,3% to 66.8+/-1,4% (13.0%). PHI 120 increased from 57.2+/-1,5% up to 63.1+/-1,4% (10.3%).

In the control group indicators phagocytic activity has not changed.

The results of testing indicate the strengthening of the immunostimulating effect on the basis of the composition containing ellagic acid and beta-1,3/1,6-glucan or oligosaccharides (first, second, third) compared to the individual components of the composition (the group's fourth, fifth and sixth).

Composition for enhancing the immune system on the basis of ellagic acid, characterized in that it further contains beta-1,3/1,6-glucan or oligosaccharides.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to pharmacology and can be used in veterinary science and medicine for chemotherapy. There is disclosed immunostimulating and antioxidant lithium composition containing lithium ascorbate and lithium aspartate in percentage ratio 50:50.

EFFECT: expansion of the list of low-toxicity immunomodulators applicable for manufacture of drugs.

1 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly therapy, and can be applied in chronic disease treatment. Method involves causative agent extraction or determination of antibodies to causative agents or extraction of genetic components from blood, body fluid or smear. Treatment is performed by vaccine drugs specific to one or several identified causative agents, additionally immunomodulators are administered.

EFFECT: activated repair processes, arrested development of disease state of organs and systems due to elimination of identified pathogen from organism and to immune correction.

3 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly granulocytopoiesis stimulants, radioprotectors and immune stimulants. Under cytostatics effect Cyclophilin A amplifies granulocyte precursor removal from marrowbone and stimulates granulocytopoiesis.

EFFECT: in case of sublethal radiation, cyclophilin A stimulates migration of marrowbone stem elements and participates in recovery of blood cells and immune system, and shows redioprotection properties.

4 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: medicinal agent contains alpha and/or beta and/or gamma human recombinant interferon, tocopherol acetate or other tocopherol derivatives, ascorbic acid and/or its salts, pantothenic acid or calcium pantothenate, or dexapanthenol, riboflavin or levocarnitine, and orotic acid and/or ornithine or its derivative - citrulline malate, or Glutoxim, antibacterial, antimycotic agents, additives: emulsifiers, stabilisers, preservatives, antioxidants and base. The formulation is suppositories in certain component ratio.

EFFECT: efficiency for severe infectious diseases and mixed infections.

9 cl, 18 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, be more specific to oncology, and concerns the substances stimulating maturing of dendritic cells (DC). Application of fucoidan from Fucus evanescens or polysaccharide composition from Fucus evanescens consisting of fucoidan in amount of 60-80% and poly-mannuronic acid in amount of 20-40%, as an agent possessing ability to induce maturing of dendritic cells is offered. The declared fucoidan preparations have a standardised composition and, hence, possess direct biological effect. They keep the properties for long time (3 years).

EFFECT: increase of DC functional activity under the influence of the declared substances.

8 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary science, in particular, to ways of reception of immunomodulatory and antiseptic compounds for prevention and treatment of infectious diseases of animals. The way of reception of a complex immunotropic antiseptic preparation for prevention and treatment of infectious diseases of animals includes mixing of an amber acid, novocaine, Dorogov's antiseptic-stimulator of the second fraction and formalin in water at a following parity of components, wt %: amber acid 1; DAS №2 4; novocaine 0.25; formalin 0.4; the distilled water - the rest, and sterilisation using autoclave treatment which is performed in a 1 atm regimen. Within 20 minutes. The received compound possesses antiseptic, immunomodulatory and trophicostimulating activity at a parenteral way of introduction.

EFFECT: rising of efficiency of the received preparation at treatment and prevention of infectious diseases of animals.

2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to creation of immunogene compositions and vaccines for prevention or treatment of the infections caused by Gram-negative bacteria. The immunogene compositions containing a transferrin-binding fiber and Hsf, and a way of their reception are offered. It is shown, that the combination of these two antigens synergically influences on production of antibodies with high activity in the analysis of bactericidal Serum. The composition can be used in vaccines against Gram-negative bacteria, including Neisseria meningitides, Neisseria gonorrhoeae.

EFFECT: creation of immunogene compositions and vaccines for prevention or treatment of the infections caused by Gram-negative bacteria.

56 cl, 10 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention concerns area of medical products, in particular to application of complex bonds of iron (III) with carbohydrates or their derivatives for reception of a medical product for improvement of immune protection and-or activity of a brain at patients without an anaemia caused by deficiency of iron or deficiency of iron in which complex bond of iron (III) is iron (III)-polymaltose complex bond or complex bond of iron (III) with a product of oxidation one or several maltodextrins.

EFFECT: development of preparations for improvement of immune protection and-or activity of a brain at patients without an anaemia caused by deficiency of iron or deficiency of iron.

7 cl, 1 tbl, 1 ex

FIELD: medicine; pharmacology.

SUBSTANCE: substance of technical decision seeks to produce immunopotentiating composition based on nanotechnology products, specifically fullerenes and superdispersed diamond powders (nanodiamonds) produced by detonation synthesis. Composition contains modified fullerene of general formula C60-X, where C60 is fullerene nucleus, X is formylporphyrin, as well as superdispersed diamond powder in ratio as follows, wt %: porphyrin modified fullerene C60 - 50; superdispersed diamond powder - 50.

EFFECT: synergetic effect of immunopotentiating components activity with simultaneous considerable reduction in price concerning prototype composition.

2 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: autoblood is daily sampled in patient as 2 ml/kg of weight. Sampled blood is mixed with 20 ml of 0.06% sodium hypochlorite with further ultraviolet radiation with the help of "Isolda" device for 20 minutes. Then blood is intravenously injected to by drop infusion. Treatment is carried out daily for 5 days.

EFFECT: enhanced efficiency of treatment of patients with chronic obstructive bronchitis.

2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: present invention concerns coated tableted form containing a tablet centre coated with a medical agent as inhibitor DPP4 sacsaglipitin, and the method for preparing such coated tableted form. The layers that coat the tablet centre are applied as a coating polymer suspension.

EFFECT: according to the invention, coated tablets are characterised with improved chemical stability as compared to the conventional tablets.

17 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to experimental cardiopharmacology and can be used for correction of endothelial dysfunction. It is ensured by simulation of endothelial dysfunction in experiment by intraperitoneal introduction to Wistar rats of N-nitro-L-arginine methyl ester dosed 25 mg/kg within 7 days. Thus the degree of dysfunction development is estimated by the relation of endothelium independent and endothelium dependent vasodilatation. Dysfunction is corrected by intraperitoneal introduction of preparation phosphogliv lyophilisate dosed 5.0 ml/kg and 0.5 ml/kg.

EFFECT: invention provides effective correction of endothelial dysfunction in specific experimental conditions.

2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely otorhinolaryngology, and can be used in treating paratonsillar abscesses complicated with cervical lymphadenitis. Throughout a day, one antibiotic injection is introduced directly in lymph node pre-visualised by ultrasonic scanning. Other injections are introduced intramuscularly. Endolymphatic injections are applied within 2-4 days in a dose that corresponds to the single therapeutic dose.

EFFECT: invention allows controlling introduction of medicinal substances in lymph node, distribution within fat tissues surrounding lymph node, and thereby improving efficiency and safety of antibacterial therapy of the patients suffering from paratonsillar abscess complicated with cervical lymphadenitis.

3 ex

FIELD: medicine.

SUBSTANCE: invention concerns chemical and pharmaceutical industry and medicine, particularly pharmaceutical drugs applied in case of traumatic and post-operation injuries of peripheral nervous system, namely fluid and soft medicine forms of stephaglabrin drug. Invention claims pharmaceutical composition for local and external application in treatment of traumatic and post-operation injuries of peripheral nervous system, containing stephaglabrin sulfate, perfluoro-organic compound emulsion and at least one target additive out of: reparative process stimulation agent, anesthetic, antioxidation agent, vitamins, biogenic elements, or mix thereof, and hydrophilic base if necessary, at the following component ratio (wt %): stephaglabrin sulfate - 0.001-2.0; target additive - 0.000001-60.6; perfluoro-organic compound emulsion - 5.0-90.0, the rest is hydrophilic base.

EFFECT: enhanced therapeutic effect and its duration.

8 cl, 16 ex

FIELD: veterinary.

SUBSTANCE: method involves processing of affected udder teats with ointment of the following composition, wt %: pefloxacin - 1.0÷1.5, metronidazole - 1.0÷1.5, chlorohexidine digluconate - 0.005÷0.01, organosilicon glycerohydrogel Si(C3H703)4·xC3H8O3·yH2O, where 5≤x≤6, 28≤y≤30 - up to 100. Ointment is applied onto udder teat skin twice per day after milking for 7-10 days daily in the dosage of 0.5-1.0 g per teat.

EFFECT: accelerated healing process, reduced risk of further udder teat damage without deterioration of milk quality or stopping of mechanised milking and livestock productivity reduction.

1 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to novel pharmaceutical composition in form of lyophilizate. Lyophilizate is obtained by lyophilic drying of emulsion of "oil in water" type based of lecithin. Emulsion contains badly soluble in water or in oil active substance, effective quantity of antioxidant, emulsion stabiliser, dimethylsulphoxide, copolymer of lactide and glycolide and additive, which prevents enlargement of emulsion particles during freezing. Lyophilizate is characterised by high stability when dissolved by infusion liquids.

EFFECT: reconstructing of emulsion is realised during not more than 15 minutes and without application of additional equipment, restored emulsion containing not less than 80% of particles with size less than 200 nm.

19 cl, 3 dwg, 3 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: according to the present invention, there is provided a pharmaceutical composition for local and external application when treating traumatic and post-operation injuries of peripheral nervous system. The composition is characterised by content of stephaglabrine sulphate and hydrophilous base as dryer or physiologically acceptable solution of dryers combined with components ensuring compliance with required capabilities depending in drug dosage form with the following ration of components (wt %): stephaglabrine - 0.001-2.0; the rest is hydrophilous base.

EFFECT: extended and enhanced therapeutic effect.

3 cl, 19 ex

FIELD: medicine.

SUBSTANCE: according to the present invention, there is provided a pharmaceutical composition for local and external application when treating traumatic and post-operation injuries of peripheral nervous system. The composition is characterised by stephaglabrine sulphate content, emulsion of perfluoro-organic compounds and if required hydrophilous base with the following component ration (wt %): stephaglabrine sulphate 0.001-2.0; emulsion of perfluoro-organic compounds - 5.00-90.00; the rest is hydrophilous base.

EFFECT: enhanced therapeutic effect, enlarged application range of known medicine stephoglabrine, integration of skin integument and absence of soreness during the treatment, strengthened disposition to treatment.

3 cl, 15 ex

FIELD: medicine.

SUBSTANCE: therapy of the patients suffering from chronic lower limb ischemia involves sampling the autogenic blood cell mass in amount 6-8% of total blood volume by discrete plasmapheresis. Then the autogenic cell mass is incubated with pentoxifylline 10 ml during 20 min at room temperature with ATP 2 ml added. The prepared mass is reinfused to the patient. Thereafter, Vasaprostan is introduced in a dose 40 mkg/day with physiologic saline 200 ml as intravenous infusion during 3 hours. Therapeutic course is 10-15 daily procedures.

EFFECT: higher clinical effectiveness with regard to the pathology due to correction of hemodynamic disorders in an ischemic focus and improvement of rheological properties blood in the absence of absolute indications to surgical procedure or inability thereof.

2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for making a parenteral preparation contains a pharmaceutical agent, a water-soluble polymer, a nonpolymeric additive and a solvent. The water-soluble polymer is chosen from the group: dextran, gelatin, 2-hydroxyethy starch, poly(N-vinylpyrrolidone), human blood serum albumin or their mixture. The nonpolymeric additive is chosen from the group: (C10-C18)acyl-sorbite, oligooxyethylene(C10-C18)acyl-sorbite, (C10-C18)alkyl oligooxyethylene glycol ester. The solvent represents mixed water and ethanol, or dimethyl sulphoxide, or N-methyl-2-pyrrolidone, or 2-pyrrolidone. The pharmaceutical agent, said water-soluble polymer, nonpolymeric additive and residual solvent are found in the preparation as a noncovalent complex.

EFFECT: improved bioavailability of the pharmaceutical agents and therapeutic dose decline.

2 cl, 1 dwg, 1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to analytical chemistry. A method is proposed for detecting polyatomic cations, which form complexes with heparin. The method is realised as follows. Solutions of polyatomic cations are added to 1% agarose gel, and solution of heparin is put into basins. Electrophoresis is carried out and the gel is tinged with 0.1% solution of alcian blue in 3% acetic acid.

EFFECT: complex formation is indicated by coloured peaks of precipitation.

8 ex, 1 tbl, 1 dwg

Up!